COMBINING TO CURE®
Arcus is at the forefront of designing precision combinations in the pursuit of cures for patients living with cancer.
Arcus is at the forefront of designing precision combinations in the pursuit of cures for patients living with cancer.
NSCLC
mCRPC
CRC
PDAC
UPPER GI
Advanced Malignancies
Healthy Participants
Domvanalimab
(DOM)
FC-SILENT ANTI-TIGIT ANTIBODY
UPPER GI
UPPER GI
NSCLC
NSCLC
NSCLC
NSCLC
Quemliclustat
CD73 Inhibitor Small Molecule
PDAC
Etrumadenant
(ETRUMA)
Dual A2a/A2b Adenosine Receptor Antagonist Small Molecule
CRPC
CRC
NSCLC
AB521
HIF-2𝛂 Inhibitor
Healthy Participants
Advanced Malignancies, Including RCC
Etrumadenant: Dual A2aR/A2bR Antagonist Small Molecule
Quemliclustat: CD73 Inhibitor Small Molecule
Domvanalimab: TIGIT mAb
Zimberelimab: PD-1 mAb
These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.
ABBREVIATIONS:
atezo: atezolizumab; bev: bevacizumab; carbo/pem: carboplatin/pemetrexed; doce: docetaxel; dom: domvanalimab; enza: enzalutamide; etruma: etrumadenant; gem/nab-pac: gemcitabine/nab-paclitaxel; nivo: nivolumab; pembro: pembrolizumab; PLD: pegylated liposomal doxorubicin; quemli: quemliclustat; rego: regorafenib; SOC: standard of care; zim: zimberelimab;
CRC=colorectal cancer; CRPC=castrate-resistant prostate cancer; GI=gastrointestinal; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma; RCC=renal cell carcinoma
PARTNERSHIPS & COLLABORATIONS:
(a) In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The parties will co-develop Gilead-optioned programs globally, and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.
(b) In September 2017, Arcus and Taiho announced an option and license agreement. Taiho has an option to Arcus’s programs arising during the 5-year term for Japan and certain other Asian territories (excluding China).
(c) Arcus and AstraZeneca are collaborating on PACIFIC-8, a registrational Phase 3 clinical trial, to evaluate domvanalimab plus durvalumab (Imfinzi®) in unresectable Stage 3 NSCLC with curative intent, where durvalumab is standard of care.
*+/- biologic
Etrumadenant: Dual A2aR/A2bR Antagonist Small Molecule
Quemliclustat: CD73 Inhibitor Small Molecule
Domvanalimab: TIGIT mAb
Zimberelimab: PD-1 mAb
These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.
ABBREVIATIONS:
atezo: atezolizumab; bev: bevacizumab; carbo/pem: carboplatin/pemetrexed; doce: docetaxel; dom: domvanalimab; enza: enzalutamide; etruma: etrumadenant; gem/nab-pac: gemcitabine/nab-paclitaxel; nivo: nivolumab; pembro: pembrolizumab; PLD: pegylated liposomal doxorubicin; quemli: quemliclustat; rego: regorafenib; SOC: standard of care; zim: zimberelimab
CRC=colorectal cancer; CRPC=castrate-resistant prostate cancer; GI=gastrointestinal; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma; RCC=renal cell carcinoma
PARTNERSHIPS & COLLABORATIONS:
(a) In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The parties will co-develop Gilead-optioned programs globally, and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.
(b) In September 2017, Arcus and Taiho announced an option and license agreement. Taiho has an option to Arcus’s programs arising during the 5-year term for Japan and certain other Asian territories (excluding China).
(c) Arcus and AstraZeneca are collaborating on PACIFIC-8, a registrational Phase 3 clinical trial, to evaluate domvanalimab plus durvalumab (Imfinzi®) in unresectable Stage 3 NSCLC with curative intent, where durvalumab is standard of care.
*+/- biologic
Anti-CD39
Exo-nucleotidase
CD39 is a key enzyme in removing ATP from the tumor microenvironment; increased ATP may enhance the adaptive immune response against tumors.1
Additional undisclosed targets.
AXL Inhibitor
Tyrosine kinase
AXL overexpression is associated with tumor resistance to chemotherapy and immunotherapy drugs.2
Additional undisclosed targets.
References: 1. Moesta et al. Targeting CD39 in Cancer. Nature Reviews Immunology volume 20, pages739–755 (2020). 2. Axelrod HD, Valkenburg KC, Amend SR, et al. AXL is a putative tumor suppressor and dormancy regulator in prostate cancer. Mol Cancer Res. 2019;17(2):356-369.
